AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01614821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: Taken orally, once daily in the morning
Study NCT04608513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1014-6470
Description: Soft capsules for oral administration
Study NCT04608513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft capsules for oral administration
Study NCT02766023 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
Study NCT03692624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Heart Rate Variability Biofeedback
Study NCT02941601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV
Study NCT02764164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Active tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
Study NCT04156217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV-TCR-T cells
Description: EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
Study NCT04537273 — intervention group
Intervention type: OTHER
Intervention: Descriptive and analytical
Study NCT02340728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP with SEMS plus radiofrequency ablation
Study NCT02340728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with SEMS alone (standard of care)
Study NCT00551551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with physiotherapist
Description: 8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
Study NCT00551551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written information about kegel exercises
Description: Information about pelvic floor disorders prevention with personal pelvic floor exercises
Study NCT00551551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information about kegel exercises
Description: Information about pelvic floor disorders prevention with personal pelvic floor exercises
Study NCT04123990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron status testing
Description: Iron status testing
Study NCT01368809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml at induction 1-2 ml boluses as needed
Study NCT01368809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
Study NCT02817230 — intervention group
Intervention type: DRUG
Intervention: Statin
Study NCT02719431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin
Study NCT02719431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: K-877
Study NCT03443128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
Study NCT03341572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5,10 and 15cmH2O positive end expiratory pressure
Description: every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
Study NCT03341572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5,10 and 15cmH2O positive end expiratory pressure
Description: every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
Study NCT00904293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided dose determination
Description: Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
Study NCT00904293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-genotype guided warfarin dosing
Description: Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
Study NCT04582942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEG
Description: Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
Study NCT04582942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG+lactulose
Description: On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
Study NCT01657097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCS
Study NCT01657097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02615821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Contrasting
Description: n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
Study NCT02615821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Contrasting
Description: n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
Study NCT01219049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine
Description: 1000 mg / day
Study NCT01219049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine
Description: 2000 mg / day
Study NCT01219049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study NCT02855671 — intervention group
Intervention type: DEVICE
Intervention: Infrared thermal imaging
Description: Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
Study NCT02198092 — intervention group
Intervention type: OTHER
Intervention: Epi proColon Testing
Description: Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.
Study NCT00146081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management
Description: Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
Study NCT00146081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Management
Description: Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
Study NCT02183922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microencapsulated conjugated linoleic acid
Description: The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
Study NCT02183922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microencapsulated fish oil
Description: The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
Study NCT02183922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: light fruit jam
Description: The placebo group received light fruit jam (15 g/day) during 12 weeks.
Study NCT03149614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spine Mobilizations
Description: Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
Study NCT03149614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vertebral Resonant Oscillation
Description: The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992.
Study NCT02471950 — intervention group
Intervention type: PROCEDURE
Intervention: 2.5 % Isoflurane administration
Description: Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
Study NCT02354781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1.CMV.huFollistin344
Description: Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
Study NCT03082950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: polymerase chain reaction
Description: PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
Study NCT04269005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of the SCCM
Description: Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
Study NCT02761486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 325mg aspirin per day
Study NCT02761486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo in matching capsules
Study NCT00427089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate
Description: 2L gut lavage solution
Study NCT02941601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT00427089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Phosphate solution (NaP)
Description: 45 ml solution; BID
Study NCT00448435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW815SF HFA MDI
Description: salmeterol and fluticasone propionate combination
Study NCT00448435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW815SF HFA MDI
Description: salmeterol and fluticasone propionate combination
Study NCT00448435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol and fluticasone propionate
Description: salmeterol + fluticasone propionate
Study NCT01839721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifilact®
Description: placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
Study NCT01839721 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02119754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plurogel PN
Study NCT03351881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Description of Organ Donation Policy
Description: Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.
Study NCT02615704 — intervention group
Intervention type: DEVICE
Intervention: Active group with MEMS
Description: Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
Study NCT02615704 — intervention group
Intervention type: DEVICE
Intervention: Active group without MEMS
Description: Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
Study NCT02615704 — intervention group
Intervention type: DEVICE
Intervention: Control group with MEMS
Description: Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
Study NCT02615704 — intervention group
Intervention type: DEVICE
Intervention: Control group without MEMS
Description: Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
Study NCT04088383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amnios™ RT
Description: Acellular human allograft
Study NCT04088383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sterile saline
Study NCT02232620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
Study NCT02830997 — intervention group
Intervention type: DEVICE
Intervention: Stereotactic guidance system
Study NCT02231021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alogliptin
Description: alogliptin 25 mg add-on background medication metformin
Study NCT02231021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30 mg add-on background medication metformin
Study NCT02231021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alogliptin + pioglitazone
Description: alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
Study NCT01481623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Constitution of a biological bank
Description: Blood samples for the constitution of a biobank (DNA, RNA, serum)
Study NCT01481623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metabolic studies
Description: oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
Study NCT04199234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product consumption
Description: Consumption of an encapsulated iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
Study NCT04199234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparator product consumption (Iron sulphate)
Description: Consumption of iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
Study NCT04621396 — intervention group
Intervention type: OTHER
Intervention: Observational screening study
Study NCT04693260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Visual Acuity with a Hand-held Device Supported by Mobile App.
Description: The Insight will be compared to a standard ETDRS eyechart
Study NCT02684513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Carbohydrate Beverage
Description: The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
Study NCT02684513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rehydration beverage
Description: The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
Study NCT00037869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131 Metaiodobenzylguanidine
Study NCT01978353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Training
Description: Participants receive memory training to facilitate learning and memory of face-name associations
Study NCT01978353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants receive information about memory functioning and aging
Study NCT03984903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia Learning of Exercises
Description: Patients learn exercise from multimedia content.
Study NCT03984903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Learning of Exercises
Description: Physiotherapist teach exercises to patients
Study NCT03984903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
Study NCT03984903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
Study NCT03984903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Patients do at least 20 minutes motor control exercise in a day at home.
Study NCT03984903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: Patients do at least 20 minutes motor control exercise in a day at home.
Study NCT00331123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
Study NCT02941601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study NCT02015637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: single dose
Study NCT02015637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: single dose
Study NCT01100801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 with cisplatin
Study NCT01100801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 with oxaliplatin
Study NCT02641782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibody ch14.18
Description: 17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
Study NCT02641782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibody ch14.18
Description: 17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
Study NCT02641782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
Study NCT02641782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: 250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5